Connect with us

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Webinar/Online

Thursday, February 5, 2026 at 2:00pm ET - 2:30pm ET
Add this event to your calendar

Info

Topic

The treatment landscape of muscle-invasive bladder cancer (MIBC) has undergone a paradigm shift with the advent of combination immunotherapy approaches. Join us in the first session of the Hot Topics in Genitourinary Cancer series for an interactive live webinar designed to support oncologists and urologists in navigating this rapidly evolving treatment landscape. Led by two nationally recognized experts, this session will delve into current treatment modalities, emerging evidence for combination immunotherapy from recent clinical trials, and novel drug-delivery systems. Participants will also explore strategies for appropriate patient selection, systemic therapy sequencing, and multidisciplinary collaboration to optimize patient outcomes. Don't miss this opportunity to interact with peers and gain unique insights into practical approaches to enhance clinical treatment decision making to improve patient-centered care.

Credits Offered

This event offers 0.5 contact hours to attendees.
Accreditation Info: AANP.

Additional Information

Join us in the first session of the Hot Topics in Genitourinary Cancer series for an interactive live webinar designed to support oncologists and urologists in navigating this rapidly evolving treatment landscape.

Speakers

Matthew Galsky
Matthew Galsky MD

Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies.

Fed Ghali
Fed Ghali MD

Assistant Professor of Urology
Division of Urologic Oncology
Yale School of Medicine
New Haven, Connecticut

Interested In Attending This Event?